Primary aldosteronism and its impact on the generation of arterial hypertension, endothelial injury and oxidative stress

Journal of Pediatric Endocrinology and Metabolism

Volumn 23, Issue 4, 2010, Pages 323-330

  Martinez Aguayo, Alejandro ^a   Carvajal, Cristian A ^a   Campino, Carmen ^a   Aglony, Marlene ^a   Bolte, Lillian ^a   Garcia, Hernán ^a   Fardella, Carlos E ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Arterial hypertension; Endothelial injury; Oxidative stress; Primary aldosteronism

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; CORTICOTROPIN; CYTOCHROME P450C17; DEXAMETHASONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUDROCORTISONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; HYDROGEN PEROXIDE; I KAPPA B; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PLASMINOGEN ACTIVATOR INHIBITOR; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE; STEROID 11BETA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE; SUPEROXIDE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADENOMA; ADRENAL CORTEX; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONGENITAL ADRENAL HYPERPLASIA; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; ENZYME ACTIVITY; ENZYME DEFICIENCY; FIBRINOLYSIS; GENE MUTATION; GENETIC PREDISPOSITION; HEART MUSCLE FIBROSIS; HIGH SODIUM INTAKE; HORMONE RESISTANCE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; LEUKOCYTE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; OXYGEN TENSION; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; REVIEW; SIGNAL TRANSDUCTION; SODIUM RESTRICTION; SODIUM RETENTION; T LYMPHOCYTE; VASOCONSTRICTION; VASODILATATION; WATER RETENTION; BLOOD; HYPERALDOSTERONISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; OXIDATIVE STRESS;

EID: 77954662981     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem.2010.052     Document Type: Review

References (65)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.
2. Marcun NV, Gregorio A. A diagnostic approach for the child with hypertension. Pediatr Nephrol 2005; 20: 499-506.
3. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity and the prevalence of hypertension in school-aged children. Pediatrics 2004; 113: 475-82
4. Hansen M, Gunn P, Kaelber D. Underdiagnosis of Hypertension in Chidren and Adolescents. JAMA 2007; 298: 874-9.
5. Aglony I M, Arnaiz G P, Acevedo B M, Barja Y S, Márquez U S, Guzmán A B, Berríos C X. [Blood pressure and family history of hypertension in children from Santiago, Chile]. Rev Med Chil. 2009; 137(1):39-45.
6. Garcia H, Diaz C, Bancalari R, Zamorano J, Cerda V, Fernandez M, Garbin F, Marchant M, Munoz P, Cavada G, Valenzuela MT, Arteaga JC. Prevalence of Overweight, Obesity and Arterial Hypertension in a Representative Survey of Children and Adolescents in Santiago, Chile. Poster P3-208. The Endocrine Society 90th Annual Meeting, San Francisco, USA, June 15-18, 2008.
7. Juárez-Rojas JG, Cardoso-Saldaña GC, Posadas-Sánchez R, Medina-Urrutia AX, Yamamoto-Kimura L, Posadas-Romero C. Blood pressure and associated cardiovascular risk factors in adolescents of Mexico City. Arch Cardiol Mex. 2008; 78: 384-91.
8. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. A detectable cause of curable "essential" hypertension. JAMA 1965; 193:200-206
9. Mosso L, Fardella C, Montera J, Rojas P, Sánchez O, Rojas V, Rojas A, Huete A, Soto J, Foradori A. High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension. Rev Med Chile 1999; 127:800-806
10. Cortés P, Fardella C, Oestreicher E, Gac H, Mosso L, Soto J, Foradori A, Claverie X, Ahuad J, Montera L. Excess of mineralocorticoids in essential hypertension: clinical-diagnostic approach. Rev Med Chile 2000; 128(9); 955-61
11. Mosso L, Carvajal C, González A, Barraza A, Avila F, Montera J et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-5.
12. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004; 89:1045-50.
13. Fardella CE, Mosso L. Primary aldosteronism. Clin Lab. 2002; 48:181-90.
14. Montera J, Soto J, Fardella C, Foradori A, Valdés G. Measurement of low levels of plasma rennin activity. A methodological improvement Rev Med Chil. 1998; 126:151-4.
15. Fardella CE, Montera J, Mosso L. [Hypertension and mineralocorticoids. Usefulness of renin and aldosterone measurements].Rev Med Chil. 1999 May; 127:604-10.
16. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902.
17. Schwartz Gl, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/ renin ratio. Clin Chem 2002; 48: 1919-23. (Pubitemid 35222749)
18. Rayner Bl, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronaism. South African Medical Journal 2000; 90: 394-400.
19. Carvajal CA, Romero DG, Mosso LM, Gonzalez AA, Campino C, Montera J and Fardella CE. Biochemical and genetic characterization of 11Beta-hydroxysteroid dehydrogenase type 2 in low-renin essential hypertensives. Journal of Hypertension 2005, 23:71-77.
20. Gordon RD. Primary aldosteronism. J Endocrinol Invest 1995; 18: 495-511.
21. Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 1992; 89: 8327-31.
22. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S et al. A chimaeric 11 beta-hydroxylase/ aldosterone synthase gene causes glucocorticoidremediable aldosteronism and human hypertension. Nature 1992; 355: 262-5.
23. Macconnachie AA, Kelly KF, Mcnamara A, Loughlin S, Gates LJ, Inglis GC et al. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab 1998; 83: 4328-31.
24. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995; 207: 565-71.
25. Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med. 2001 94(8):378-83. (Pubitemid 32738676)
26. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pérez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
27. Pitt B, Remme W, Zannad F, Neaton J, Martínez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-21.
28. Milliez P, Girerd X, Plouin PF, Blacher J, Safar Me, Mourad Jj. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-8.
29. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M et al.. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-9.
30. Cooper ME. The role of the renin-angiotensin aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004; 17(11pt2): 16S-20S; quiz A2-4.Review
31. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertension 2001; 19: 829-42.
32. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenol-type in the rat heart. Am J Physiol Heart Circ Physiol. 2002; 283(5):H1802-10
33. Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad F. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation. 2009; 119(18):2471-9.
34. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME. Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol. 2007 27(4):799-805
35. Arima S, Kohagura K, Xu Hl, Sugawara A, Abe T, Satoh F et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-63.
36. Stehr CB, Carvajal CA, Lacourt P, Alcaíno H, Mellado R, Cattani A, Mosso LM, Lavandera S, Fardella CE. [Subclinical endothelial inflammation markers in a family with type I familial hyperaldosteronism caused by a de novo mutation] Rev Med Chil. 2008; 136: 1134-40
37. Brown N. Aldosterone and vascular inflammation Hypertension 2008; 51:161-167
38. Struthers A, MacDonald T. Review of aldosterone - and angiotensin II induced target organ damage and prevention Cardiovascular research 2004; 61: 663-670
39. Liu, S. L., Schmuck, S., Chorazcyzewski, J. Z., Gros, R., Feldman, R. D. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003; 108: 2400-2240.
40. Maron BA, Zhang YY, Handy DE, Beuve A, Tang SS, Loscalzo J, Leopold JA. Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells. J Biol Chem. 2009; 284: 7665-7672.
41. Van Der Poll T, Van Deventer SJ, Pasterkamp G, Van Mourik JA, Buller HR, Ten Cate JW: Tumornecrosis factor induces von Willebrand factor release in healthy humans. Thromb Haemost 1992; 67:623-626.
42. Navarro-González JF, Mora C, Muros M, Jarque A, Herrera H, García J. Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. J Hypertens. 2008; 26: 2168-75.
43. Carvajal CA, Herrada AA, Castillo CR, Contreras FJ, Stehr CB, Mosso LM, Kalergis AM, Fardella CE. Primary aldosteronism can alter peripheral levels of TGF-beta and TNF-alpha. J Endocrinol Invest. 2009; 32(9):759-65.
44. Staermose S, Marwick TH, Gordon RD, Cowley D, Dowling A, Stowasser M. Elevated serum interleukin 6 levels in normotensive individuals with familial hyperaldosteronism type 1. Hypertension. 2009; 53: e31-2.
45. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R: Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290: 1084-1089.
46. Arnaiz P, Acevedo M, Barja S, Aglony M, Guzmán B, Cassis B, Carvajal J, Moreno M, Navarrete C, Berríos X. Adiponectin levels, cardiometabolic risk factors and markers of subclinical atherosclerosis in children. Int J Cardiol. 2010; 138(2):138-44.
47. White PC, Curnow KM, Pascoe L. Disorders of steroid 11 beta-hydroxylase isozymes. Endocr Rev. 1994 Aug; 15(4):421-38.
48. White PC, Dupont J, New MI, Leiberman E, Hochberg Z, Rösler A. A mutation in CYP11B1 (Arg-448-His) associated with steroid 11 beta-hydroxylase deficiency in Jews of Moroccan origin. J Clin Invest. 1991 May; 87(5):1664-7.
49. Fardella CE, Miller WL. Molecular biology of mineralocorticoid metabolism. Annu Rev Nutr. 1996; 16:443-70.
50. Yanase T, Simpson ER, Waterman MR. 17 alpha-hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition. Endocr Rev. 1991; 12(1):91-108.
51. Fardella CE, Zhang LH, Mahachoklertwattana P, Lin D, Miller WL. Deletion of amino acids Asp487-Ser488-Phe489 in human cytochrome P450c17 causes severe 17 alpha-hydroxylase deficiency. J Clin Endocrinol Metab. 1993; 77(2): 489-93.
52. Fardella CE, Hum DW, Homoki J, Miller WL. Point mutation of Arg440 to His in cytochrome P450c17 causes severe 17 alpha-hydroxylase deficiency. Fardella CE, Hum DW, Homoki J, Miller WL. J Clin Endocrinol Metab. 1994; 79(1): 160-4.
53. White PC. Inherited forms of mineralocorticoid hypertension.Hypertension 1996; 28(6):927-36.
54. Stewart PM, Corrie JE, Shackleton CH, Edwards CR. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.J Clin Invest. 1988; 82(1): 340-9.
55. RC Wilson, ZS Krozowski, K Li, VR Obeyesekere, M Razzaghy-Azar, MD Harbison, JQ Wei, CH Shackleton, JW Funder, and MI New. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess J. Clin. Endocrinol. Metab., 1995; 80: 2263-2266.
56. Mune T, Rogerson FM, Nikkilä H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet. 1995; 10(4):394-9.
57. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987; 237(4812): 268-75. (Pubitemid 17095145)
58. Rupprecht R, Reul JM, van Steensel B, Spengler D, Söder M, Berning B, Holsboer F,Damm K. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol. 1993; 247(2): 145-54.
59. Wilson RC, Dave-Sharma S, Wei JQ, Obeyesekere VR, Li K, Ferrari P, Krozowski ZS, Shackleton CH, Bradlow L, Wiens T, New MI. A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci U S A. 1998-95(17): 10200-5
60. Stewart PM. Mineralocorticoid hypertension. Lancet 1999; 353(9161): 1341-7.
61. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, Whorwood CB. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet. 1996; 347(8994): 88-91.
62. Charmandari E, Kino T. Novel causes of generalized glucocorticoid resistance. Horm Metab Res. 2007; 39(6):445-50.
63. Syed AA, Halpin CG, Irving JA, Unwin NC, White M, Bhopal RS, Redfern CP, Weaver JU. A common intron 2 polymorphism of the glucocorticoid receptor gene is associated with insulin resistance in men. Clin Endocrinol (Oxf). 2008; 68(6):879-84.
64. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton RP. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000; 7; 289(5476):119-23.
65. Rafestin-Oblin ME, Souque A, Bocchi B, Pinon G, Fagart J, Vandewalle A. The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. Endocrinology. 2003; 144(2):528-33.